360Dx

360Dx is a publication from GenomeWeb, an independent news source located in New York. Since its inception in 1997, GenomeWeb has been dedicated to supporting the worldwide community of scientists, tech experts, and leaders involved in creating and utilizing cutting-edge tools for molecular biology research and diagnostics. GenomeWeb operates as a division of Crain Communications.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1145019

United States

#501261

Health/Biotechnology and Pharmaceuticals

#439

Traffic sources

Monthly visitors

Articles

Artera Bullish on Prostate Cancer Test Following NYS Approval, Impending Registry Study

2 days ago | 360dx.com | Kelsy Ketchum

NEW YORK – Startup firm Artera is continuing to make commercial progress with its artificial intelligence-based prostate cancer test thanks to a recent approval from the New York State Department of Health as well as the upcoming launch of a registry study to further boost evidence of the test's efficacy.
Caris Life Sciences Looking to Expand Customer Base, Further Commercial Reach With IPO

1 week ago | 360dx.com | Kelsy Ketchum

NEW YORK – Caris Life Sciences went public this week with the goals of further expanding its customer base and getting closer to profitability, executives said in an interview after the company's stock began trading on the Nasdaq Global Select Market on Wednesday.
PanGia Biotech Preparing Urine-Based Prostate Cancer Test for Commercialization

2 weeks ago | 360dx.com | Kelsy Ketchum

NEW YORK – With new data and plans for additional clinical validation in the works, liquid biopsy firm PanGia Biotech is making strides toward commercialization of its urine-based prostate cancer assay in India and the US.
Phase Scientific Plans Large Study of Urine-Based HPV Test as Cervical Cancer Screen

2 weeks ago | 360dx.com | Forest Ray

NEW YORK – Molecular diagnostics company Phase Scientific is gearing up to launch a large-scale study of its urine-based human papillomavirus (HPV) test in China for cervical cancer screening on the heels of positive clinical validation data earlier this year.
Saga Diagnostics Jumps Into MRD Market with Tumor-Informed Breast Cancer Test

2 weeks ago | 360dx.com | Greg Cima

NEW YORK – Starting with a molecular residual disease (MRD) test for early-stage breast cancer patients, Saga Diagnostics said that it is bringing to market a multi-cancer testing platform that targets patient-specific structural variants to determine whether treatments are working and detect recurrence months to years ahead of clinical signs.
Point-of-Care MDx Sepsis Test Being Developed With Plans for US Commercialization

3 weeks ago | 360dx.com | Greg Cima

NEW YORK – Canadian researchers have developed a point-of-care molecular blood test to quickly predict which patients in the emergency department or ICU are likely to develop sepsis within 24 hours.
ASCO: Memorial Sloan Kettering Researchers Develop Pap-Based Endometrial Cancer Test

3 weeks ago | 360dx.com | Kelsy Ketchum

Some U.S. state privacy laws offer their residents specific consumer privacy rights, which we respect as described in our privacy statement. To opt-out of our making available to third parties information relating to cookies and similar technologies for advertising purposes, select "Opt-Out". To exercise other rights you may have related to cookies, select "More Info" or see this "Privacy Request" link.
ASCO: Razor Genomics Test Shows Promise for Chemotherapy Selection in High-Risk Lung Cancer Patients

3 weeks ago | 360dx.com | Kelsy Ketchum

CHICAGO – In an abstract presented at the American Society of Clinical Oncology's annual meeting on Saturday, researchers demonstrated that Razor Genomics' RiskReveal 14-gene assay could help clinicians determine which patients with early-stage non-squamous non-small cell lung cancer should undergo adjuvant chemotherapy after surgery.
OncoHost Developing NeutroFlow Test for Guiding Cancer Therapy Selection

4 weeks ago | 360dx.com | Justin Petrone

NEW YORK – OncoHost, an Israeli biotechnology company, is working with three European medical centers to produce a new flow cytometry test to predict patient response to immunotherapies for five cancer indications, according to Michal Harel, OncoHost's vice president of translational medicine.
Alzheimer's Field Grappling With Risks, Benefits of Blood Testing in Primary Care

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – In May, the US Food and Drug Administration (FDA) issued the first 510(k) clearance of a blood-based test for Alzheimer's disease, a development that is likely to drive broader reimbursement and use of such products.

360Dx journalists

Adam Bonislawski

Edward Winnick

Greg Cima

Julia Karow

Kelsy Ketchum

Madeleine Johnson

Molika Ashford

Turna Ray

Contact details

Address

123 Example Street

City, Country 12345

Phone

+1 (555) 123-4567

Socials

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Outlet metrics

Articles

Artera Bullish on Prostate Cancer Test Following NYS Approval, Impending Registry Study

Caris Life Sciences Looking to Expand Customer Base, Further Commercial Reach With IPO

PanGia Biotech Preparing Urine-Based Prostate Cancer Test for Commercialization

Phase Scientific Plans Large Study of Urine-Based HPV Test as Cervical Cancer Screen

Saga Diagnostics Jumps Into MRD Market with Tumor-Informed Breast Cancer Test

Point-of-Care MDx Sepsis Test Being Developed With Plans for US Commercialization

ASCO: Memorial Sloan Kettering Researchers Develop Pap-Based Endometrial Cancer Test

ASCO: Razor Genomics Test Shows Promise for Chemotherapy Selection in High-Risk Lung Cancer Patients

OncoHost Developing NeutroFlow Test for Guiding Cancer Therapy Selection

Alzheimer's Field Grappling With Risks, Benefits of Blood Testing in Primary Care

360Dx journalists

Contact details

Address

Phone

Email

Email Patterns

Website

Socials

Traffic locations